UNSPSC 51144402: Pipradrol

This classification denotes a piperidine C18H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6E46VR9Y2, chemically known as .alpha.,.alpha.-diphenyl-2-piperidinemethanol hydrochloride, but more generally known as pipradrol hydrochloride, which bears US NIH Compound Identifier 66008. European Medicines Agency schedules Pipradrol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03864MIG.

Most nations, for tariff and trade purposes, schedule pipradrol hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PIPRADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(C2CCCCC2)(C3CCCCN3)O.CL.

UNSPSC 51144402 Pipradrol is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows minimal direct alignment with pipradrol itself. Instead, the code appears in solicitations for broader pharmaceutical procurement—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance). The work solicited spans pharmaceutical supply, inventory management, wholesaler relationships, and compliance with FDA, DEA, and supply-chain security requirements such as the Drug Supply Chain Security Act.

Recent opportunities reflect activity in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to a county health building. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026, requiring compliance with cGMP, DSCSA certification, and maintenance of relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The code shows little recent activity directly tied to pipradrol procurement and warrants clarification on actual commodity scope before pursuit.